-
Avextra AG Announces Closing of Follow-On Capital Raise Supported by Existing and New Institutional Investors
BENSHEIM, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce the closing of its most recent capital raise with support from existing investors, strategic partners and new institutional investors. The funding will…
-
German Pain Association (DGS) and pharmaceutical company Avextra join forces to launch their new study OCEAN
Bensheim, Germany, January 23, 2024 – Avextra AG (“Avextra” or the “Company”), a leading European vertically-integrated manufacturer and developer of pharmaceutical cannabis-based medicines (CBMs) located in Germany, is proud to announce a joint study with the German Pain Association (DGS) focused on chemotherapy-induced neuropathic pain (CINP).
-
AVEXTRA invests up to 15 million euros in the development of new medical cannabis research in partnership with IUCS-CESPU
Lisbon, January 17th, 2024 – Avextra, the leading German manufacturer of cannabis-based medicines, has entered a strategic, long-term partnership with the Instituto Universitário de Ciências da Saúde-Cooperativa de Ensino Superior Politécnico e Universitário (IUCS-CESPU) focused on Research & Development (R&D) of regulator approved medicines based on the cannabis plant.
-
Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients
Bensheim, 18.10.2023 – Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the aim of designing robust clinical trials for proprietary Cannabis-based medicines that can achieve regulatory approval.
-
Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria
Bensheim, 14.9.2022 – Der führende Anbieter von cannabisbasierten Arzneimitteln aus Deutschland mit neuem Namen: Aus Eurox wird Avextra…
-
Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy
Bensheim, 14.9.2022 – Der führende Anbieter von cannabisbasierten Arzneimitteln aus Deutschland mit neuem Namen: Aus Eurox wird Avextra…
-
Germany unveils scaled-down recreational cannabis legalization plan
Marla Luther is the new Chief Strategy Officer at Eurox Pharma, the leading European vertically-integrated manufacturer of cannabis-based medicines, which will operate under the Avextra name.
-
Avextra AG Announces Closing of EU 17 Million Capital Raise
Bensheim, 14.9.2022 – Der führende Anbieter von cannabisbasierten Arzneimitteln aus Deutschland mit neuem Namen: Aus Eurox wird Avextra…
-
Avextra Successfully Exports Oil-Based Cannabis Medicines to the United Kingdom
Bensheim, Gemünden (Wohra) and Gauting, 09. November 2022 – Die Unternehmen haben es sich zum Ziel gesetzt, das erste Inhalationsdevice zur Verabreichung von standardisierten Cannabisextrakten vorzubereiten, das den neuen europäischen Richtlinien für Medizinprodukte entspricht…
-
Medical Device Submission für ein Inhalationsdevice
Bensheim, Gemünden (Wohra) and Gauting, 09. November 2022 – Die Unternehmen haben es sich zum Ziel gesetzt, das erste Inhalationsdevice zur Verabreichung von standardisierten Cannabisextrakten vorzubereiten, das den neuen europäischen Richtlinien für Medizinprodukte entspricht…